Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAP-232 in metastatic kidney cancer
NCT00422786Phase 2Completed
- Sponsor
- Thallion Pharmaceuticals Inc.
- Start
- Mar 2007
- Primary completion
- Mar 2008
- Countries
- 1
01
Overview
A Phase 2 trial of TT-232 in renal cell carcinoma (RCC), sponsored by Thallion Pharmaceuticals Inc.. Started Mar 2007; status: completed.
02
Drugs
TT-232
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00422786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00422786.